Program
dexketoprofen
Also written as “Dexketoprofen Trometamol + Tramadol Hydrochloride”, “Dexketoprofen/Tramadol-single dose” and “Dexketoprofen/Tramadol-multiple doses”.
Its studies are mostly in Acute Pain · Dysmenorrhea · Low Back Pain · Venous Thrombosis · Pain, led by 2 companies.
Drug pageDexketoprofen: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Menarini Groupits history only | 60 open or running | phase 4since May 13, 2016 | Feb 28, 2011 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 20 open or running | phase 3since Jul 29, 2021 | Jul 29, 2021 | none ahead |
Also a collaborator on its studies: Simbec Research and PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Laboratorios Silanes S.A. de C.V. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2021First study: phase 3 study in Acute Low Back PainFirst studyNCT05001555 · 174 enrolled · Mexico
- Oct 14, 2026Phase 3 study in Primary DysmenorrheaNCT07901894 · 130 enrolled · Mexico
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 2 Laboratorios Silanes S.A. de C.V. leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07901894Primary Dysmenorrhea · Mexico | 3 | Completed | May 7, 2026 | 130 |
| NCT05001555Acute Low Back Pain · Mexico | 3 | Completed | Apr 24, 2023 | 174 |
How it is read
Names in the registry
- “Dexketoprofen Trometamol + Tramadol Hydrochloride”, 4 entries
- “Dexketoprofen/Tramadol-single dose”, 2 entries
- “Dexketoprofen/Tramadol-multiple doses”, 2 entries
- “Dexketoprofen / Butylscopolamine in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.)”, 1 entry
- “Dexketoprofen/Vitamin B”, 1 entry
Conditions, from the studies’ own filings
- Acute Pain, 4 studies
- Dysmenorrhea, 1 study
- Low Back Pain, 1 study
- Venous Thrombosis, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.